Роль омега-3 полиненасыщенных жирных кислот в лечении прогрессирующих заболеваний почек


Е.В. Кулина

ФГБУ “Московский НИИ педиатрии и детской хирургии” Минздравсоцразвития России, Москва
В обзоре представлено значение омега-3 полиненасыщенных жирных кислот в лечении хронических прогрессирующих заболеваний почек у детей.

Литература


1. Kromann N., Green A. Epidemiological studies in the Upernavic district Grenland: incidence of some chronic disease 1950–1974. Acta Med Scand. 1980; 208; 401–406.
2. Dyeberg J., Band H.O., Hjorne N. Fatty acid composition of the plasma lipids in Grenland Eskumos. Am Clin-Nutr. 1975; 28: 958–966.
3. León H., Shibata M.C., Sivakumaran S. et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2008; 337: 2931.
4. Steiber A. Omega-3 fatty acids may benefit dialysis patients. Clin. Hypertens 2010; 32: 137–144.
5. Fekete K., Marosvolgyli T., Jakobik V. et al. Methods of assessment of n–3 long-chain polyunsaturated fatty acid status in humans: a systematic review1–5 Am J Clin Nutr 2009; 89: 2070S–2084S.
6. Reynolds J.L., Wetze D.L.l, O©Hara T.M. Human health implications of omega-3 and omega-6 fatty acids in blubber of the Bowhead Whale (Balaena mysticetus). J. Arctic. 2006; 59 (2): 155–164.
7. Riediger N.D., Othman R.A., Suh M. et al. A systemic review of the roles of n-3 fatty acids in health and disease. J. Am. Diet Assoc. 2009; 109(4): 668–679.
8. Сalder P.C. Fatty acids metabolism and eicosanoid synthesis. Clinical. Nutrition. 2001; 20: 1–5.
9. Левачев М.М. Значение жира в питании здорового и больного человека: В: Тутельян В.А., Самсонов М.А. (ред.) Справочник по диетологии. М.: Медицина. 2002. С. 25–32.
10. Leaf A., Weber P.C. Cardiovascular effects of n-3 fatty acids. N. Engl. J. Med. 1988; 318(9): 549–557.
11. von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc. Health Risk Manag. 2006; 2(3): 251–262.
12. Kromhout D. Diet and cardiovascular diseases. J. Nutr. Health. Aging. 2001; 5(3): 144–149.
13. Djousse L., Folsom A.R., Province M.A.et al. and Blood Institute Family Heart Study. Dietary linolenic acid and carotid atherosclerosis. Am. J. Clin. Nutr. 2003; 77 (4): 819–825.
14. Rosenberg T.H. Fish food to calm the heart. N. Engl. J. Med. 2002; 346: 1102–1103.
15. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001; 294: 1871–1875.
16. Brink C., Dahlen S.E., Drazen J. et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev. 2003; 55: 195–227.
17. Bos C.L., Richel D.J., Ritsema T. et al. Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell. Biol. 2004; 36: 1187–1205.
18. Reiffel J.A., McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am. J. Cardiol. 2006;98: 50–60.
19. Северин. Е.С. Биохимия. М. Гэотар-Мед. 2004.
20. Fischer S., Weber P.C. Thromboxane (TX)A3 and prostaglandin (PG) I3 are formed in man after dietary eicosapentaenoic acid: identification and quantification by capillary gas chromatography-electron impact mass spectrometry. Biomed Mass Spectrom. 1985; 12: 470–476.
21. Martyn B.J. Prostaglandins, leukotrienes, and lipoxins: biochemistry, mechanism of action, and clinical applications Plenum Press, New York. 1985.
22. Serhan C.N. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr. Opin. Clin. Nutr. Metab. Care. 2005; 8: 115–121.
23. Bazan N.G. The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling. Cell. Mol. Neurobiol. 2006; 26: 4–6.
24. Bazan N.G. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr. Opin. Clin. Nutr. Metab. Care. 2007; 10: 136–141.
25. Levant B., Ozias M.K., Jones K.A. et al. Differential effects of modulation of docosahexaenoic acid content during development in specific regions of rat brain. Lipids. 2006; 41: 407–414.
26. Ortmann O., Catt K.J., Schulz K.D. et al. Modulatory action of progesterone and progesterone antagonists on hypothalamic-pituitary function. Hum Reprod. 1994; 9(Suppl. 1): 53–62.
27. Kotani S., Sakaguchi E., Warashina S. et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res. 2006; 56: 159–164.
28. Catalan J., Moriguchi T., Slotnick B. et al. Cognitive deficits in docosahexaenoic acid-deficient rats. Behav. Neurosci. 2002; 116: 1022–1031.
29. Akbar M., Calderon F., Wen Z. et al. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci USA. 2005; 102: 10858–10863.
30. Gonzalez-Periz A., Planaguma A., Gronert K. et al. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 2006; 20: 2537–2539.
31. German O.L., Insua M.F., Gentili C. et al. Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway. J Neurochem. 2006; 98: 1507–1520.
32. Lukiw W.J., Bazan N.G. Docosahexaenoic acid and the aging brain. J. Nutr. 2008; 138: 2510–2514.
33. Khalfoun B., Thibault F., Watier H. et al. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv. Exp. Med. Biol. 1997; 400: 589–597.
34. Li Q., Ma J., Tan L. et al. Effect of docosahexaenoic acid on interleukin-2 receptor signaling pathway in lipid rafts. Sci. China C Life Sci. 2006; 49: 63–72.
35. Pan H.C., Kao T.K., Ou Y.C. et al. Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J. Nutr. Biochem. 2009; 20:715–725. 36. Hao C.M., Breyer M.D. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int. 2007; 71: 1105–1115.
37. Dwyer J.H., Allayee H., Dwyer K.M. et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 2004; 350: 29–37.
38. Clark W.F., Parbtani A., Philbrick D.J. et al. Chronic effects of omega-3 fatty acids (fish oil) in a rat 5/6 renal ablation model. J. Am. Soc. Nephrol. 1991; 1: 1343–1353.
39. Hagiwara S., Makita Y., Gu L. et al. Eicosapentaenoicacid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice:involvement of MCP-1 suppression and decreased ERK1/2 and p38phosphorylation. Nephrol. Dial. Transplant. 2006; 21: 605–615.
40. Sabry A., El-Dahshan K., El-Hussieni A. Prevention of chronic cyclosporine nephrotoxicity in Sprague-Dawley rats: role of colchicine and omega-3-fatty acids. Int. Urol. Nephrol. 2007; 39: 271–273.
41. Garman J.H., Mulroney S., Manigrasso M. et al. Omega-3 fatty acid rich diet prevents diabetic renal disease. Am. J. Physiol. Renal. Physiol. 2009; 296: F306–F316.
42. An W.S., Kim H.J., Cho K.H. et al. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am. J. Physiol. Renal. Physiol. 2009; 297: F895–F903.
43. De Caterina R., Capriori R., Giannessi D. n-3 fatty acids reduce proteinuria in patients with chronic glomerular disease. Kidney. Int. 1993; 44: 843–850.
44. Henderson J. Dietary considerations in chronic kidney disease. Nat. Med. J. 2010;2(9): 12.
45. Svensson M., Schmidt E.B., Jørgensen K.J. et al. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrol. Dial. Transplant. 2008; 23 (9): 2918–2924.
46. Вознесенская Т.C., Кутафина Е.К. и др. Влияние омега-3 полиненасыщенных жирных кислот на показатели липидного обмена у детей с нефротическим синдромом. Вопросы детской диетологии.
2003; 1(2): 90–93.
47. Kwan B.C., Kronenberg F., Beddhu S. et al. Lipoprotein metabolism and lipid management in chronic kidney disease. J. Am. Soc. Nephrol. 2007; 18: 1246.
48. Weiner D.E., Sarnak M.J. Managing dyslipidemia in chronic kidney disease. J. Gen. Intern. Med. 2004; 19: 1045.
49. Keith D.S., Nichols G.A., Gullion C.M. et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organiza- tion. Arch. Intern. Med. 2004; 164: 659–663.
50. Ordonez J.D., Hiatt R.A., Killebrew E.J.et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993; 44: 638–642.


Об авторах / Для корреспонденции


Кулина Е.В. – аспирант отделения наследственных и приобретенных болезней почек ФГБУ “Московский НИИ Педиатрии и детской хирургии” Минздравсоцразвития России.
kulina_ev@mail.ru


Похожие статьи


Бионика Медиа